NCT03828838View on ClinicalTrials.gov

Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

November 1, 2019

Study Completion Date

November 1, 2019

Conditions
Prostate Neoplasm
Interventions
DRUG

Lu-177 PSMA-617

Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)

Trial Locations (1)

6525GA

Radiology and Nuclear Medicine, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT03828838 - Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter